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ABSTRACT
When expressed on the surface of cells, CD47 inhibits phagocytosis of these cells 
by phagocytes. Most human cancers overexpress CD47, and antibodies to CD47 have 
shown a remarkable ability to clear a range of cancers in animal models. However, 
the mechanism by which these antibodies cause cancer cell death is unclear. We find 
that CD47 is expressed on the surface of three B-cell lines from human malignancies: 
697 (pre-B-ALL lymphoblasts), Ramos and DG-75 (both mature B-cells, Burkitt’s 
lymphoma), and anti-CD47 antibodies greatly increase the phagocytosis of all three 
cell line by macrophages. In the presence of macrophages, the antibodies cause 
clearance of the lymphoblasts within hours, but in the absence of macrophages, 
the antibodies have no effect on lymphoblast viability. Macrophages engulf viable 
lymphoblasts containing mitochondria with a normal membrane potential, but 
following engulfment the mitochondrial membrane potential is lost indicating a loss 
of viability. Inhibition of phagocytosis protects lymphoblasts from death indicating 
that phagocytosis is required for anti-CD47 mediated cell death. Blocking either the 
antibody Fc domain or Fc receptors inhibits antibody-induced phagocytosis. Antibodies 
against cell surface markers CD10 or CD19 also induced Fc-domain-dependent 
phagocytosis, but at a lower level commensurate with expression. Thus, phagoptosis 
may contribute to the efficacy of a number of therapeutic antibodies used in cancer 
therapy, as well as potentially endogenous antibodies. We conclude that anti-CD47 
antibodies induce phagocytosis by binding CD47 on lymphoblast and Fc receptors on 
macrophages, resulting in cell death by phagocytosis, i.e. phagoptosis.
INTRODUCTION
Phagocytosis is the engulfment of large (>0.5 
micron) extracellular particles by cells. Cells specialised 
in phagocytosis are termed ‘phagocytes’, and in mammals 
include macrophages, monocytes, microglia, neutrophils 
and dendritic cells [1, 2]. Particles engulfed by phagocytes 
may include other cells. Cells are phagocytosed by 
competent phagocytes if they: i) expose on their surface 
so-called ‘eat-me’ signals, such as phosphatidylserine or 
calreticulin, ii) lose so-called ‘don’t-eat-me’ signals, such 
as CD47 or surface sialylation, and/or iii) bind opsonins, 
such as complement factors or IgG antibodies [1-3]. It has 
in the past been generally assumed that phagocytes only 
phagocytose dead or dying cells [2, 3]. However, there 
are a variety of circumstances in which otherwise viable 
cells are phagocytosed and thereby killed as a result of the 
phagocytosis [4]. This type of cell death by phagocytosis, 
which we have called ‘phagoptosis’, has the defining 
characteristic that if phagocytosis is inhibited then cell 
death is prevented [4]. Examples of such phagocytic cell 
death are: physiological turnover of senescent erythrocytes 
[5, 6], neutrophil phagocytosis of bacteria [7, 8] and 
developmental loss of neurons [9, 10].
Recently it has become clear that most human 
cancer cells overexpress CD47 on their surface 
apparently to prevent themselves being phagocytosed 
[11]; their phagocytosis being promoted by the presence 
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of calreticulin on the surface of the cancer cells [12]. 
Remarkably, if CD47 is blocked by an anti-CD47 antibody 
then a variety of cancers can be cleared from mice [11-
13]. Suggested mechanisms include that the anti-CD47 
antibodies: i) induce phosphatidylserine exposure and cell 
death in the cancer cells by activating CD47 signalling 
[14, 15], ii) block the ‘don’t-eat-me’ function of CD47, 
enabling phagocytosis [11], iii) enable greater access 
of antibodies to cancer cells [16], or iv) induction of 
antibody-dependent cell-mediated cytotoxicity (ADCC) 
[17]. However, the mechanism by which anti-CD47 
antibodies affect cancers remains unclear and controversial 
[18], and this limits the development of these antibodies as 
therapeutic agents.
Acute lymphoblastic leukeamia (ALL) is 
characterized by the clonal expansion of a population of 
abnormal lymphocytes, known as lymphoblasts when they 
originate from immature cells as in precursor-B ALL, the 
most common childhood leukaemia. Cancers of mature 
B-cell phenotype (ALL and lymphoma, e.g. Burkitt’s) 
are also seen in childhood and more commonly in young 
adults. There is a need for new therapies for B-ALL and 
lymphomas that are more effective and/or cause less long-
term morbidity in survivors than the current therapy using 
DNA damaging drugs [19].
Chao et al [13] showed that anti-CD47 antibodies 
induce phagocytosis of ALL lymphoblasts by 
macrophages in culture and clearance of lymphoblasts 
in mice, suggesting that the antibody might be used 
therapeutically for ALL. However, it remains unclear: 
a) how the antibodies are inducing phagocytosis, in 
particular whether the Fc domain is involved, and b) 
how the lymphoblasts die, in particular whether the 
lymphoblast are phagocytosed alive or dead, and thus 
whether phagocytosis is the cause of death. The answers 
to these questions are fundamental to the design and use 
of therapeutic antibodies. Weismann and colleagues’ 
concept of ‘programmed cell removal’ [20] of cancer cells 
by phagocytes as a result of antibody binding does not 
distinguish between clearance of live or dead cancer cells, 
and thus does not identify the cause of death.
In the work described here, we sought to 
determine: a) whether anti-CD47 antibodies could induce 
phagocytosis of pre-B-ALL lymphoblasts and mature 
B-cell blasts by macrophages, b) whether anti-CD47 
antibodies induce phagocytosis of otherwise live cells 
and thereby result in their cell death by phagocytosis, 
and c) how anti-CD47 antibodies induce phagocytosis. 
We conclude that: anti-CD47 antibodies do induce 
phagocytosis of pre-B-ALL lymphoblast and mature 
B-cells and the induced cell death is by phagocytosis, 
i.e. phagoptosis. The Fc domain appears key to this 
phagoptosis and similar cell death is observed with 
antibodies directed against CD 10 and 19 suggesting that 
exploitation of this mechanism may have therapeutic 
potential.
RESULTS
Anti-CD47 antibody induces phagocytosis of B 
lymphoblasts by macrophages
CD47 has been reported to be overexpressed 
on a variety of cancer cell types in order to suppress 
phagocytosis of these cells. We tested whether CD47 was 
expressed on the surface of three different cell lines using 
a well characterised mouse antibody to human CD47 
(clone B6H12). We found that CD47 was expressed on the 
surface of the three human B-cell lines used: 697 (pre-B-
ALL), Ramos and DG-75 (both mature B-cells, Burkitt’s 
lymphoma)) (Figure 1A).
We next tested whether the antibody would induce 
phagocytosis of these cells by a human macrophage cell 
line (U937). The anti-CD47 antibody greatly increased 
phagocytosis by macrophages of all three cell lines as 
indicated by the uptake of fluorescently-labelled cells 
measured by flow cytometry (Figure 1B). The antibody 
also increased the phagocytosis by the macrophages 
of two other pre-B-ALL cell line NALM6 and REH, 
although to a lesser extent than the phagocytosis of 697 
cells (Supplementary Figure 1).
We then selected the 697 lymphoblasts to co-
incubate with macrophages at a 1:1 ratio, and determined 
whether the antibody-induced uptake would significantly 
deplete the population of lymphoblasts. 6 hours of co-
culture resulted in no depletion of lymphoblast in the 
absence of antibody, but in the presence of antibody about 
75% of the lymphoblasts were lost after 6 hours (Figure 
1C). This suggests that the anti-CD47 antibody might be 
useful in the treatment of B-ALL.
CD47 on the surface of a cell is thought to block 
phagocytosis of that cell by engaging the SIRPα receptor 
on the surface of phagocytes, resulting in inhibition of 
phagocytosis. We therefore tested whether SIRPα and 
CD47 were expressed on the U937 macrophages, and 
found that both SIRPα and CD47 were both expressed on 
the macrophage surface (Figure 1D).
The antibody does not directly kill lymphoblasts, 
but induces macrophage phagocytosis of live 
lymphoblasts, resulting in death by phagocytosis
The anti-CD47 antibody might either a) kill 
the lymphoblasts, which could then induce their own 
phagocytosis via for example phosphatidylserine exposure, 
or b) induce the phagocytosis of otherwise viable 
lymphoblasts, resulting in their death by phagocytosis. We 
tested whether the anti-CD47 antibody induced apoptosis 
and/or necrosis of the lymphoblasts by measuring 
phosphatidylserine exposure with annexin V and necrosis 
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with propidium iodide. However, there was no change in 
the proportion of apoptotic or necrotic lymphoblasts when 
exposed to anti-CD47 over 6 hours (Figure 2A). Thus 
the antibody alone did not induce apoptosis, necrosis or 
phosphatidylserine exposure of the lymphoblasts. Note 
also that >95% of lymphoblasts were viable (neither 
apoptotic or necrotic) after 6 hours of incubation in the 
presence or absence of antibody (Figure 2A). Even after 
48 hours of incubation, the antibody induced no additional 
cell death or change in the number of viable cells (neither 
annexin V or propidium iodide positive), (Figures 2A & 
2B), suggesting that the antibody has no effect on viability 
or proliferation in the absence of macrophages.
The antibody might induce the macrophages to kill 
the lymphoblasts prior to phagocytosis. It is not known 
whether the cells induced to be phagocytosed by the anti-
CD47 antibody are alive or dead at the time of engulfment, 
and therefore whether cell death precedes or follows 
engulfment. To test this, we stained the lymphoblasts 
with JC-1 to assess their mitochondrial membrane 
Figure 1: CD47 is expressed on the surface of malignant B-lymphocytes, and anti-CD47 antibodies increase their 
phagocytosis by macrophages dramatically reducing their numbers within 6 hours. A. Antibody binding to 697 (pre-B 
lymphoblast cell line), Ramos and DG-75 (Burkitt lymphoma mature B lymphocyte cell lines) incubated with 10 µg/mL of isotype control 
or B6H12 anti-CD47 antibody, then AF488-conjugated secondary before analysing by flow cytometry. Representative example of 3 
experiments. The % of each cell type binding the anti-CD47 antibody is given, and was gated on live cells (propidium iodide negative). 
B. U937 cells were matured into macrophages with 10nM PMA for 24 hours and further 48 hours incubation. Target B cells were stained 
with TAMRA, and macrophages with CFSE before co-incubating for 2 hours at 1:1 ratio with isotype or anti-CD47 B6H12 at 2 µg/mL. 
Phagocytosis assessed by measuring % of double positive macrophages. N≥4. Bars are mean ± SEM, *** / **** p < 0.001 / 0.0001, 
compared to isotype for that cell line. C. Phagocytosis assay prepared as above, but 697 stained with JC-1 and U937 with Höechst 33342. 
The number of free, live 697 cells was counted at 0 and 6 hours after addition of anti-CD47 antibody or nil. N = 4. D. Antibody binding to 
U937-derived macrophages incubated with 10 µg/mL of isotype control, B6H12 anti-CD47 antibody or anti-SIRPα antibody, then AF488-
conjugated secondary before analysing by flow cytometry. Representative example of 3 experiments. The % of cells binding the anti-CD47 
antibody and anti-SIRPα antibody are given, and was gated on live cells (propidium iodide negative). N = 3. Bars are mean ± SEM, * p < 
0.05 compared with control. 
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potential at the time of engulfment by the macrophages. 
In cells with normal, polarised mitochondria, the 
mitochondria fluoresce red, but this changes to green if 
the mitochondria depolarise. Almost all lymphoblast 
cells had intact mitochondrial membrane potential at 
the time of engulfment, but lost this potential about 30 
mins after engulfment (Figure 3, Supplementary videos 
1 and 2). When multiple videos were analysed, most of 
the lymphoblasts incubated with anti-CD47 antibody for 
6 hours were phagocytosed by macrophages (Figure 3B). 
For each individual lymphoblast that was phagocytosed, 
over 90% had intact mitochondrial membrane potential 
at the time that they were being phagocytosed (Figure 
3C), but after phagocytosis almost all lost this potential 
(Figure 3D), although a small but significant proportion 
re-emerged from the phagocytes alive. In summary, almost 
all the lymphoblasts were engulfed alive, but subsequently 
died.
If the cause of cell death is phagocytosis, then 
inhibiting phagocytosis should prevent cell death. To test 
this we added cytochalsin D, which inhibits phagocytosis 
by blocking actin polymerisation. Addition of 1µM 
cytochalasin D inhibited the uptake of lymphoblasts into 
macrophages by about 80% (Figure 4A), and increased 
the number of free (unphagocytosed) lymphoblasts at 
the end of the co-incubation by about 80% (Figure 4B), 
and of those free lymphoblasts about 90% were viable 
(not apoptotic or necrotic) (Figure 4C). Thus blocking 
phagocytosis of the lymphoblasts left viable lymphoblasts, 
indicating that in the absence of inhibitor the cause of 
lymphoblast death was phagocytosis.
Anti-CD47 antibody induces phagocytosis via the 
Fc domain
The anti-CD47 antibody bound to both the 
lymphoblasts and the macrophages (Figure 1). Thus the 
anti-CD47 antibody might be acting on the lymphoblasts 
or macrophages or both to induce phagocytosis. We 
tested whether incubating the anti-CD47 antibody with 
either cell type, followed by washing to remove unbound 
antibody could increase phagocytosis. Pre-incubation of 
lymphoblasts with antibody increased their subsequent 
phagocytosis three-fold (Figure 5A). Whereas pre-
incubation of the macrophages with antibody had no effect 
on the subsequent phagocytosis of lymphoblasts (Figure 
5A). For comparison, when the antibody was added to 
both cell types at the start of the co-incubation, then the 
phagocytosis was increased five-fold (Figure 5A). This 
indicates that antibody binds to the lymphoblasts and this 
then mediates uptake into the macrophages.
The anti-CD47 antibody might increase 
phagocytosis by activating CD47 receptor signalling. 
Figure 2: Anti-CD47 antibodies alone do not induce death or affect proliferation of 697 cells. 697 cells were incubated for 6 
or 48 hours with 2 μg/mL anti-CD47 or isotype control antibodies before staining and counting cells with annexin V for phosphatidylserine 
exposure (apoptosis) and propidium iodide (necrosis). Cells not staining with annexin V or propidium iodide were counted as viable. A. 
The % of necrotic and apoptotic cells is plotted. B. The number of viable cells in the same experiment is plotted. N = 3. Bars are mean ± 
SEM. NS = p > 0.05. 
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To test this, we added the CD47 receptor agonist 
thrombospondin-1 or a derivative peptide 4N1K, known 
to change the conformation of CD47 and strongly activate 
CD47 signalling [21]. Neither thrombospondin nor 4N1K 
affected macrophage phagocytosis of lymphoblasts in 
the absence of anti-CD47 antibody (Figure 5B & 5C), 
suggesting that activation of CD47 signalling is not 
sufficient to induce phagocytosis. Note however that we 
cannot be sure that thrombospondin activated CD47 in this 
experiment. 
Figure 3: Time lapse imaging indicates that anti-CD47 antibody induces macrophage engulfment of live lymphoblasts. 
697 lymphoblasts were stained (mitochondria red/green) with JC-1 and U937 macrophages stained (nuclei blue) with Höechst 33342, and 
co-incubated at a 1:1 ratio and time-lapse imaged every 150 seconds for 6 hours with live/dead judged by change in red/green fluorescence 
of JC-1 and phagocytosis judged on phase images. A. Representative images to illustrate. The red arrow marks the first target cell, the blue 
arrow a second. Numbers by the red arrow is ratio of red:green fluorescence; a value < 1 suggests loss of cell viability. B. Outcome of 697 
cells present in first frame. Four videos were analysed (Average 97 target cells and 96 macrophages in the first frame) following the fate of 
lymphoblasts present in first frame of video C. Number and viability (presence or absence of mitochondrial membrane potential) of 697 
cells at time of phagocytosis (ie bright green bar of B). D. Outcome of those 697 cells apparently phagocytosed alive (i.e. bright green bar 
of C). “Dies” means loss of mitochondrial membrane potential, “live” means retains potential until end of video, “exits” means lymphoblast 
leaves macrophage, “moves out of view” means cell left the image frame. Data is shown as means ± SEM for at least 3 independent 
experiments performed in duplicate. * / ** p < 0.05 / 0.01 compared with control. Scale bar is 50 μM.) 
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As 4N1K and the anti-CD47 antibody have the 
same target, CD47, we tested whether 4N1K affected 
the phagocytosis induced by the anti-CD47 antibody. 
We found that at low doses, 4N1K mildly increased 
the phagocytosis induced by anti-CD47 antibody, 
while at high concentrations 4N1K mildly inhibited the 
phagocytosis induced by anti-CD47 antibody (Figure 5C). 
As 4N1K had no effect on phagocytosis in the absence of 
the anti-CD47 antibody, this suggests that 4N1K binding 
to CD47 affects antibody binding or signalling via CD47.
The antibody might work through its antigen-
binding Fab component, or its Fc receptor-binding Fc 
component, or it might require both. To investigate 
what role the Fc portion of the anti-CD47 antibody was 
playing, we blocked this with anti-Fc F(ab’)2 fragments 
that specifically bind and block mouse Fc. The uptake 
of lymphoblasts into macrophages induced by the anti-
CD47 antibody was completely prevented by blocking 
its Fc using anti-mouse Fc F(ab’)2 fragments raised in 
goat or rabbit (Figure 6A). Similarly, the loss of free 
(unphagocytosed) lymphoblasts induced by antibody was 
prevented by the anti-Fc F(ab’)2 fragments (Figure 6B).
We next fragmented the anti-CD47 antibody and 
isolated the F(ab’)2 fragment lacking the Fc portion. This 
anti-CD47 F(ab’)2 fragment had no effect on phagocytosis, 
whereas the intact antibody stimulated phagocytosis of 
lymphoblasts by U937 macrophages (Figure 6D). This 
confirms that the Fc portion of the anti-CD47 antibody is 
required for the phagocytosis.
In order to test whether the anti-CD47 antibody 
would also induce phagocytosis of lymphoblasts by 
primary human macrophages, we isolated monocytes 
from fresh human blood, and differentiated these into 
macrophages, which were then incubated with 697 
lymphoblasts ± the anti-CD47 antibody. The antibody 
increased the phagocytosis of lymphoblasts by primary 
macrophages, although not to the same extent as with 
U937 macrophages (Supplementary Figure 1C). As with 
U937 macrophages, the uptake of lymphoblasts into 
primary macrophages induced by the anti-CD47 antibody 
was prevented by blocking its Fc domain using anti-mouse 
Fc F(ab’)2 fragments raised in goat and F(ab’)2 fragments 
derived from anti-CD47 did not induce phagocytosis 
(Supplementary Figure 1C).
The Fc domain of an antibody can induce 
phagocytosis via phagocytic Fc receptors on macrophages. 
We therefore blocked these receptors with a human Fc 
receptor binding inhibitor, and found that this inhibited 
anti-CD47-induced phagocytosis (Figure 6E). This 
demonstrates that Fc receptors are necessary for anti-
CD47-driven phagocytosis.
Anti-CD10 and CD19 antibodies can also induce 
phagocytosis of lymphoblasts
If the anti-CD47 antibody induces phagocytosis of 
the lymphoblast by binding both CD47 on lymphoblasts 
and Fc receptors on macrophages, then any other antibody 
that binds lymphoblasts should induce phagocytosis by the 
same means. We compared the expression level of CD47, 
CD10 and CD19 on 697, Ramos and DG-75 cells, and 
the extent to which these antibodies induced phagocytosis 
(Figure 7). The degree of phagocytosis roughly reflected 
the surface expression levels of the antigens, although the 
anti-CD19 antibody was relatively ineffective at inducing 
phagocytosis of Ramos cells (Figure 7E). This suggests 
Figure 4: Blocking phagocytosis allows survival of 697 lymphoblast cells. A. Phagocytosis assessed with flow cytometry after 
2 hours as previously. 1 μM cytochalasin D (CytoD) incubated for 30 minutes with macrophages prior to addition of 697 cells. Anti-CD47 
B6H12 used at 2 µg/mL. B. From the same samples, the number of free (unphagocytosed) 697 cells and C. their viability. N = 3, NS Not 
significant, * / **** p < 0.05 / 0.0001 compared with control, ## p < 0.01 as shown.
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Figure 5: Anti-CD47 is only effective when bound to the target cells. In the presence of anti-CD47, low dose 4N1K increases 
phagocytosis whereas higher dose inhibits. Phagocytosis assessed by flow cytometry after 2 hr co-incubation of 697 and U937-derived 
macrophages as previously. A. Anti-CD47 0.2 μg/mL, pre-incubated either with 697 cells or U937-derived macrophages for 30 minutes 
prior to washing off, or added at start of co-incubation (during). Similar results with 2 μg/mL, not shown. N = 3. B. Phagocytosis assay with 
the CD47-agonist thrombospondin (TSP) at 5 µg/mL. A range of doses showed the same result. N = 3. C. Phagocytosis assay with 4N1K 
± anti-CD47 at 2 µg/mL. N = 3. ***** p < 0.0001 compared with control, ## / #### p < 0.01 / 0.0001 as indicated, ^ p < 0.05 compared 
with anti-CD47 alone. NS Not significant. 
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that rather than needing to target a specific pathway, such 
as the CD47-SIRPα pathway, phagocytosis of cancer cells 
can be increased simply by targeting cell surface markers 
that are highly expressed. And such antibodies work by 
binding antigen on target cells and activating phagocytic 
Fc receptors on phagocytes. This is supported by our 
finding that phagocytosis was prevented by blocking either 
the Fc domain of the antibodies (Figure 6A & 6C) or the 
Fc receptors (Figures 6C, 6E & 7D).
DISCUSSION
Antibodies are rapidly becoming one of the most 
effective therapeutic options for cancer, but the mechanism 
of action is often unclear [22]. The mechanism matters 
to the design of antibodies and how they are used [23, 
24]. The anti-CD47 antibody has been suggested to 
induce phagocytosis by several potential mechanisms: 1) 
induction of phosphatidylserine exposure and/or apoptosis 
in the cancer cells by activating CD47 signalling, 2) 
blocking the ‘don’t-eat-me’ function of CD47, enabling 
phagocytosis, 3) induction of antibody-dependent cell-
mediated cytotoxicity (ADCC) and/or 4) induction of 
cell death by phagocytosis. We have shown above in 
our system that option 1 does not apply as: a) activating 
CD47 with thrombospondin-1 or 4N1K had no effect on 
phagocytosis in the absence of the antibody, and b) the 
antibody did not induce phosphatidylserine exposure, 
apoptosis or cell death in the absence of macrophages. 
Option 2 does not apply as we found that antibody-induced 
phagocytosis was prevented by either: a) blocking the Fc 
domain of the antibody, b) removing the Fc domain of the 
Figure 6: Macrophage Fc Receptor binding is necessary for anti-CD47 and anti-CD19 induced phagocytosis. 
Phagocytosis assessed by flow cytometry after 2 hour co-incubation of 697 and macrophages as previously. Antibodies used at 2 μg/mL. A. 
Fc blocking F(ab’)2 fragments incubated with anti-CD47 for 1 hour prior to use. N = 3. B. From the same experiments, the numbers of free, 
unphagocytosed, 697 target cells. C. Fc blocking F(ab’)2 fragments incubated with anti-CD19 for an hour prior to use. N = 3. D. F(ab’)2 
fragments of anti-CD47 B6H12 antibody at molar equivalent of 2 µg/mL compared with unfragmented antibody. N = 3. E. Fc Receptor 
blocker (FcR Blocker) pre-incubated with U937 cells for 30 minutes prior to assay. N = 3. ** / *** / **** p < 0.01 / 0.001 / 0.0001 compared 
with control, # / ### / #### P < 0.05 / 0.001 / 0.0001 as indicated.
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antibody, or c) blocking Fc receptors. Thus blocking CD47 
is not sufficient to induce phagocytosis in this system. Our 
data are consistent with option 4, not 3, as a) the cells were 
alive when phagocytosed, and died after phagocytosis, and 
b) blocking phagocytosis prevented cell death.
In general, antibody binding can induce death of a 
cell by: i) changing the activity of the specific antigen, 
ii) induction of antibody-dependent cell-mediated 
cytotoxicity (ADCC), e.g. by complement-mediated 
lysis, NK cells or cytotoxic T cells and/or iii) induction 
of antibody-dependent cellular phagocytosis (ADCP) [22]. 
Although ADCP can be an important mechanism of action 
of therapeutic antibodies, it is again unclear whether 
phagocytosis is the cause or consequence of cell death. 
And this issue also determines whether adaptive immunity 
to cancer via antibodies [25, 26] is in part mediated by 
phagoptosis i.e. cell death as a result of phagocytosis.
The role of the Fc portion of anti-CD47 has been 
investigated to a limited extent previously. F(ab’)2 
fragments (lacking the Fc domain) of the B6H12 
anti-CD47 clone were found sufficient to induce 
phagocytosis of Burkitt’s lymphoma cell line (Raji) by 
mouse macrophages [17], but not the phagocytosis of 
breast cancer cells by human neutrophil phagocytosis 
[16]. Several studies showed that the function blocking 
B6H12 clone increased phagocytosis, whereas the non-
function blocking 2D3 anti-CD47 clone did not induce 
phagocytosis [13, 17, 25, 27], suggesting that CD47 
function blocking is required, not just binding. However, 
it is unclear that the 2D3 clone binds with the same affinity 
as the B6H12 clone to either CD47 or Fc receptors. 
Our data are consistent with the anti-CD47 antibody 
killing cancer cells by antibody-dependent cellular 
phagocytosis (ADCP) [22]. And our results suggest that 
cancer cells may be targeted for phagocytosis simply by 
adding human antibodies that bind cancer cell surface 
Figure 7: Antibodies to three cell surface expression markers increases phagocytosis and the potency of antibodies to 
induce phagocytosis is related to expression levels. A.-C. Cells were labelled with 10 μg/mL of antibody, then AF488-conjugated 
secondary before analysing live cells by flow cytometry. Representative plots of three repeats. D.-F. Target cells were stained with TAMRA, 
and macrophages with CFSE then coincubated for 2 hours at 1:1 ratio with isotype or antibody. FcR Blocker is Fc receptor blocker, pre-
incubated with U937 cells for 30 minutes prior to assay. Anti-CD47 and anti-CD19 at 2 µg/mL, anti-CD10 at 5 µg/mL. N = 3. * / ** / *** 
/ **** p < 0.05 / 0.01 / 0.001 / 0.0001, compared with control, # as indicated, NS not significant.
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markers that are highly expressed. CD47 and CD10 appear 
to be suitable targets for pre-B-ALL and mature B-cell 
cancer. Anti-CD10 and anti-CD19 antibodies have already 
been used to deplete B-ALL lymphoblasts in vivo [28, 29], 
and ADCP might contribute to this antibody’s mechanism 
of action. If cancer cells express novel antigens on their 
surface then endogenous antibodies will bind to them, and 
the current work suggest such antibodies might contribute 
to immune defence by inducing phagoptosis.
4N1K is a peptide consisting of the 8 amino 
acid residues (RFYVVMWK) at the N terminal of 
thrombospondin-1, which is thought to bind two different 
sites on CD47 [30]. CD47 binds SIRPα from one of these 
sites, and this can be blocked by the B6H12 anti-CD47 
clone [31]. 4N1K is known to induce a conformational 
change in CD47 that can increase phagocytosis [21], 
and this might explain why low levels of 4N1K can 
increase anti-CD47-induced phagocytosis, as a result of 
increasing the binding of the antibody to CD47. Higher 
levels 4N1K might block anti-CD47-induced phagocytosis 
by blocking antibody binding at the second binding site. 
Note however that very high concentrations of 4NIK can 
change antibody binding to cells independent of CD47 
[32]. A potential application of the finding that low levels 
of 4N1K can enhance anti-CD47-induced phagocytosis 
is that this might be used to enhance anti-CD47 cancer 
therapy in vivo. However, in terms of the mechanism 
of action of the antibodies, the important point is that 
activating CD47 is not sufficient to induce phagocytosis.
In conclusion, this work demonstrates: that 
anti-CD47 causes macrophage phagocytosis of live 
lymphoblasts and their subsequent death, that other 
antibodies can also induce phagocytosis of B lymphoblasts 
and mature B malignant cells, and that antibody induced 
phagocytosis is dependent on an intact Fc domain. This 
work suggests that phagoptosis may contribute to both 
immune defence against cancer and potential therapies.
MATERIALS AND METHODS
Cell culture
697 were established in 1979 from a 12 year old boy 
with relapsed acute leukaemia (ALL). They are a pre-B 
lymphoblastic cell line and carry the genetic translocation 
t(1;19)(q23;p13) [33]. 697 cells stably infected with 
control retrovirus (697-Neo), or recombinant Bcl-2 
containing retrovirus (697- BCL2) were kindly provided 
by Professor Miyashita [34]. U937 cells were a gift from 
Professor Goodall, University of Cambridge, School 
of Clinical Medicine. 697 and U937 were cultured in 
RPMI 1640 (Life Technologies) supplemented with 10% 
foetal bovine serum (FBS, Life Technologies, UK) and 
1% penicillin/streptomycin (Sigma) at 37°C, 5% CO2. 
To induce differentiation, U937 were cultured on coated 
wells (poly-L-lysine 0.001% in PBS) for 3 days, the first 
24 hours with phorbol myristate acetate (PMA, 10 nM, 
Sigma).
Reagents
Anti-CD47 monoclonal antibody (mAb) B6H12, 
anti-CD19 mAb HIB19, anti-CD10, mouse IgG1 kappa 
isotype control and human Fc receptor binding inhibitor 
were from eBioscience. The latter inhibitor blocks binding 
of antibodies to Fc receptors on U937 macrophages (www.
ebioscience.com/human-fcr-binding-inhibitor-purified.
htm). F(ab’)2 fragments (Stratech) were used in 5:1 molar 
ratio fragment:antibody, incubated 30 minutes prior to 
use with antibodies. Cell dyes were from Sigma, except 
JC-1 from Life Technologies. 4N1K was from AnaSpec, 
thrombospondin from Athens Research and Technology. 
Cytochalasin D (Sigma) applied to stained U937 cells 30 
minutes prior to phagocytosis assay.
Phagocytosis assays
Target (lymphoblasts) and effector (matured 
U937 cells) were stained then co-cultured in a 1:1 ratio. 
Phagocytosis was either assessed with fluorescence 
microscopy (Leica DMI6000 CS microscope (HCX P1 
Fluotar 20x/0.40 dry objective (1hr) or 40x (Time lapse)), 
or flow cytometry (Accuri C6, BD Biosciences). For 
microscope images, engulfment was judged by looking 
for fragments of target cell stain contained within an 
effector cell, or judged on overlay images for time lapse. 
Analysis was performed using Image J, with four fields of 
view taken per well, performed in duplicate. Phagocytosis 
index is number of phagocytosing macrophages / Total 
number macrophages per 100 macrophages on field. 
For flow cytometry, cells were gated tightly on width to 
exclude doublets. Gating on CFSE-stained U937 cells, the 
shift into TAMRA FL1 gate was assessed. Single stained 
controls were used to set gates.
Cell surface expression
B cells were blocked with 1% BSA then incubated 
with Fc-blocked primary antibodies, washed and incubated 
with Alexa Fluor-conjugated secondary antibodies and 
analysed with Accuri C6. To identify live cells, they were 
co-stained with either PI or Annexin-V. Control staining 
was done using isotype-matched IgG and secondary 
antibodies alone.
Primary human macrophages
Human peripheral blood derived monocytes were 
isolated from buffy coat (white blood cell fraction), 
Oncotarget11www.impactjournals.com/oncotarget
obtained from the UK National Blood Service, by 
centrifugation on a Ficoll gradient, and subsequent 
selection of those cells adhering to plastic. Macrophages 
were matured from these monocytes over 8-9 days using 
50ng/mL M-CSF. Phagocytosis was assessed by flow 
cytometry after 2 hour co-incubation with 697 cells as 
previously. Antibodies were used at 5 μg/mL, or molar 
equivalent for fragmented antibody. Goat anti-mouse or 
rabbit anti-mouse F(ab’)2 fragments were pre-incubated 
with antibody for 1 hour prior to use.
Statistics
All analyses were performed with GraphPad Prism 
6, with one-way Anova with post-hoc Sidak analysis 
unless stated otherwise.
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